Use of amifostine in the therapy of osteosarcoma in children and adolescents

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 3, 2002, Pages 188-191

  Petrilli, Antonio Sergio ^a   Oliveira, Delma Tostes ^a   Ginani, Valeria Cortez ^a   Kechichian, Rita ^a   Dishtchekenian, Andrea ^a   De Medeiros Roque Filho, Werthon ^a   Tanaka, Cristiana ^a   Dias, Carlo Gonçalves ^a   De Oliveira Latorre, Maria Do Rosário Dias ^a   Brunetto, Algemir Lunardi ^a   Cardoso, Hedilene ^a   Almeida, Maria Teresa ^a   De Camargo, Beatriz ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amifostine; Children and adolescents; Osteosarcoma

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HEARING DISORDER; HUMAN; HYPOTENSION; LEUKOPENIA; MALE; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; VOMITING;

ADOLESCENT; ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; LEUKOPENIA; MALE; NEUTROPENIA; OSTEOSARCOMA; PILOT PROJECTS; RADIATION-PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 0036217971     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200203000-00006     Document Type: Article

References (18)

1. Cytoprotective agents for anthracyclines
2. The current status of toxicity protectants in cancer therapy
3. Applications of amifostine in cancer treatment
4. Osteosarcoma: Current management, local control and survival statistics IIB
5. Guidelines for the administration of amifostine
6. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
7. The importance of dose intensity in chemotherapy of metastatic breast cancer
8. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity
9. Amifostine: A review of its pharmacodynamic and pharmacokinetic properties, and the therapeutic potential as a radioprotector and cytotoxic chemoprotector
10. The current status of WR-2721 (amifostine): A chemotherapy and radiation therapy protector
11. A randomized trial of cyclophosphamide and cisplatin +/- amifostine in the treatment of advanced epithelial ovarian cancer
12. Ototoxicity in patients receiving cisplatin: Importance of dose and method of administration
13. Phase I trials of WR-2721 and cisplatinum
14. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
15. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine: Clinical experiences
16. Phase I/II trials of WR-2721 and cisplatinum
17. WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma
18. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial